Market share for coronary revascularization products has traditionally been dominated by a small handful of big players, making it easy for health systems to sole source from one specific vendor in exchange for courtesy pricing. Understandably, sourcing teams don’t expect to find substantial savings in this category, especially when the dominant vendors provide clinically similar products with comparable good outcomes.
However, the market has seen much downward price movement for drug-eluting stents across the vendor spectrum, providing new opportunities for savings that might otherwise go unnoticed. Furthermore, evidence is beginning to sway physicians’ opinions that drug-eluting stents are commodities rather than preference items, which may make it simpler to manage utilization variation when implementing product changes.
Join service line and value analysis experts Kristin Motter, MBA, BSN, RN, CHVAP, and Thomas Biel as they walk through the current coronary revascularization landscape. Kristin and Thomas will highlight potential savings opportunities and share best-practice tactics for securing the right products for your patient population at the right price.